Image credit: Canva
Prostate cancer is a condition where cells grow abnormally in the prostate; such cells may spread and cause health problems. The disease affects many men and is often found in men with high prostate-specific antigen (PSA) levels. A clinical trial led by Krishnan R. Patel, M.D., Assistant Research Physician in the Radiation Oncology Branch, is researching a new form of focal therapy for prostate cancer. Using stereotactic body radiotherapy (SBRT) delivered on two separate occasions, the trial aims to minimize the typical side effects associated with the current standard prostate cancer treatment methods. The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Debbie Nathan at (240) 764-6207 or dnathan@mail.nih.gov
Clinicaltrials.gov identifier: NCT05616650
NCI Protocol ID: 000611
Official Title: A Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate Cancer
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.